More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 as filed with the Securities and Exchange Commission on May 15, 2020. Shares of Beverly Hills-based biotech firm Capricor Therapeutics Inc. surged 253% on April 29 after the company announced test results for a drug to treat Covid-19 patients. LOS ANGELES, Aug 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- Total number of current team members an organization has on CrunchbaseTotal number of investment firms and individual investorsDescriptive keyword for an Organization (e.g. Capricor remains diligently focused on the treatment of DMD using CAP-1002. Marban continued, "We are enthusiastic and encouraged to be engaged in the development of the next generation of potential vaccines using our proprietary exosome platform. Two distinct vaccines are now in development, one using the exosomes as virus-like particles and the other using exosomes loaded with viral protein mRNAs. Capricor Therapeutics is a biotechnology company focused on the discovery, development and commercialization. LOS ANGELES, April 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics … CDCs have been the subject of over 100 peer-reviewed scientific publications and administered to approximately 200 human subjects across several clinical trials.Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

By using this site you agree to the Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14 Company to Host Conference Call, May 14, 2020, at 4:30 p.m. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. Manufacturing Associate I Capricor Therapeutics, Inc. Los Angeles, CA 6 minutes ago Over 200 applicants. VP, Medical Affairs. Quality Control Manager Capricor Therapeutics, Inc. Los Angeles, CA 6 minutes ago 47 applicants. The FDA has continued to encourage us to conduct a Phase III study, however at this time, we are still discussing the pathway forward for this program with the FDA.

"We had a very successful first half of 2020, marked by continued achievements in our expanding cell and exosome programs. VP, Medical Affairs Principia Biopharma San Francisco, CA. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.